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Abstract
Introduction With the growing number of adult cancer
survivors, there is increasing need for information that links
potential late and long term effects with specific treatment
regimens. Few adult cancer patients are treated on clinical
trials; however, patients previously enrolled in these trials
are an important source of information about treatment-
related late effects.
Methods Focusing on colorectal cancer survivors, we used
the database from five phase III randomized clinical trials
from the National Surgical Adjuvant Breast & Bowel
Project (NSABP) to recruit and enroll long term survivors
in a study of late health outcomes and quality of life. We
describe the challenges to recruitment of patients more than
5 –20 years after treatment.
Results Sixty-five NSABP treatment sites were invited to en-
roll patients in the study. Sixty participated with the potential to
recruit 2,408 patients. We received registration forms on only
976 patients (41%) of whom 744 (76%) expressed interest in
participating and 708 completed interviews (95% of those
expressing interest; 29% of total potential sample). There were
multiple barriers to recruitment (difficulty locating patients,
lack of institutional commitment, lack of patient interest).
Conclusions Patients treated on clinical trials are an
important potential source for examining the late effects
of cancer treatments. Retrospective recruitment has sub-
stantial limitations. In the future, mechanisms should be
established for prospective long-term follow-up to identify
and understand the frequency and type of late effects
associated with cancer treatments.
Implications for Cancer Survivors As cancer patients are
living longer, it will be important to learn from participants
in clinical trials whether or not specific treatment regimens
are associated with any serious late effects.
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Recruitmentbarriers
There has been increasing attention called to the need for
more systematic information on the late effects of cancer
treatment, due to the growing number of cancer survivors
and the complexity of contemporary cancer treatments. The
2005 Institute of Medicine report, From Cancer Patient to
Cancer Survivor: Lost in Transition [1], called for more
research to identify who is at risk for long-term sequelae
and how the consequences of treatment might be mitigated.
Until recently, most studies of cancer survivors have used
convenience samples or tumor registry databases for
recruitment [2-5]. When survivors are recruited in this
way, there may be little information on the treatment
exposures that occurred many years earlier, making it
difficult to connect specific treatments with late effects.
Furthermore, if there are dose, treatment, or scheduling
factors that are responsible for a late effect, they may not be
apparent without detailed treatment information.
One potential way to obtain a more accurate picture of the
causal relationship between cancer treatments and late effects
is to recruit cancer survivors who participated in a cancer
treatment clinical trial, where the treatments were delivered
according to a pre-specified protocol, and accurate treatment
records retained that may explain whether the patient’sl a t e
effectoutcomesarelinkedtothepriortreatment.Clinicaltrials
often assign patients to two or more competing treatment
strategies, and as a result, the survivors may be examined for
differences in outcomes that could be directly related to the
earlier treatment. The only serious limitation of studying
survivors who participated in a cancer clinical trial is that they
representa selectminorityofindividuals whoqualifiedfor the
trial and were willing to participate. Nevertheless, the fact that
treatments were assigned at random eliminates the potential
biases inherent in examining long-term outcomes in either
tumor registry samples or convenience cohorts.
Although long-term follow-up of patients treated on
National Cancer Institute (NCI) funded clinical trials
w o u l db ei d e a l ,w i t hc o l l e c t i o no fd a t ao nl o n g - t e r m
functional outcomes and comorbid conditions, few resour-
ces have been available to allow this to occur prospec-
tively. As a result, long term survivor studies that have
used this mechanism to identify and assess long-term
cancer survivors have largely required supplementary
funding, and have not built prospective follow-up into
the main trial protocol [6-9]. Thus, participants in these
studies often form another “convenience sample” since not
all potentially eligible patients participate; however, data
on specific treatments are more accurate and certainly can
provide more insight into the potential linkage between
treatment and late effects.
As part of a study designed to describe the long term and
late effects of treatment for colon and rectal cancers in
patients treated on 5 separate clinical trials conducted by
the National Surgical Adjuvant Breast and Bowel Project
(NSABP), we examined the barriers to recruitment of
survivors identified from the clinical trials database.
Colorectal cancer (CRC) survivors account for 10% of the
estimated 11.1 million cancer survivors in the United States
today, with few studies on the quality of life in individuals
with this cancer [5, 10, 11]. Given the limited data on long-
term survivorship outcomes in CRC, we designed a study
that would use the database of the NSABP to examine this
group of survivors. The selected trials spanned a 20 year
period in terms of enrollment, and as such could provide
data on very long-term survivors who had received
adjuvant therapy (radiation and chemotherapy) during
different treatment eras. However, this strength also posed
a challenge for locating and consenting individuals who
may have lost contact with the facility that provided their
cancer care. In this report we describe the procedures
developed to use the cooperative group database to identify
and recruit survivors, as well describe the logistical issues
surrounding recruitment and enrollment of long-term
survivors in this type of research. Finally, we suggest
strategies to enhance the collection of late effects data from
future participants in cancer clinical trials.
Methods
Study design
With external funding from the American Cancer Society, a
grant entitled “Patient Reported Outcomes in Long Term
Survivors with Colon and Rectal Cancer” facilitated the
funding of an NSABP Protocol Study LTS-01 to investigate
important issues in long-term (5+ years) colon and rectal
cancer survivors, by examining three types of patient-
reported outcomes (quality of life, function, and symptoms)
and their predictors. We used a modification of the Andersen
Behavioral Model to conceptualize and identify the data to
be collected, as well as the analyses to be performed [12].
To overcome inherent difficulties associated with recruit-
ing a long-term survivor sample, this study used five
previously completed NSABP colon and rectal cancer trials
to identify a well-characterized cohort of survivors. These
survivors were recruited from closed NSABP adjuvant
therapy trials that spanned a 20-year period. There were
two rectal cancer adjuvant trials, which were the oldest of
the studies included. R-02, compared adjuvant MeCCNU,
vincristine, and 5-FU (MOF) with and without radiation
therapy, to adjuvant leucovorin and 5-FU, with and without
radiation therapy, in patients with Dukes’ B and C rectal
138 J Cancer Surviv (2009) 3:137–147cancer. The trial opened in August 1987 and closed to
accrual in December 1992. R-02 was closed to follow-up
on April 14, 2004. R-03, compared preoperative multi-
modality therapy (5-FU plus leucovorin plus radiation
therapy) in patients with operable rectal cancer to postop-
erative radiation therapy with the same chemotherapy, with
accrual starting in June 1993 and closing in June 1999.
Although these rectal cancer trials had low enrollment and
small numbers of survivors available, so little was known
about these survivors that we chose to attempt to contact
them anyway.
There were three colon cancer adjuvant trials: C-05,
which compared 5-FU and leucovorin with 5-FU and
leucovorin plus interferon (IFN)-alpha 2a, was opened to
accrual in October 1991 and was closed to accrual in
February 1994; C-06, compared oral Uracil/Ftorafur (UFT)
and leucovorin to 5-FU and leucovorin, and was opened to
accrual in February 1997 and closed to accrual in March
1999; C-07, compared 5-FU plus leucovorin plus oxalipla-
tin (FLOX) to 5-FU plus leucovorin (FL) and was activated
February 2000, and closed to accrual in November 2002.
C-07 was a contemporary trial, with some patients just
reaching the five year eligibility time point during the
course of our study, and we were much more optimistic
about recruiting them as a result.
Detailed clinical, treatment, and quality of life data
already collected in each trial were available to conduct
longitudinal analyses (baseline quality of life data were
available from two colon cancer adjuvant trials). The
benefit of this strategy was the accurate information about
initial treatment, as well as a representative North American
patient population. Other recognized challenges that were
anticipated in preparing the grant and protocol were the
need to obtain institutional review board (IRB) approval to
approach survivors at each of the North American centers
who enrolled patients on these trials. Although each
institution would only need to locate and consent patients,
the inertia and administrative burden in doing so was
recognized, and funds were made available to the institution
for obtaining IRB approval, as well as locating and
consenting patients. All of the research data collection
was done through centralized telephone interview, to
minimize the burden on institutions. The goal of all of
these administrative activities was to facilitate the success-
ful recruitment of these long-term survivors who may not
have had recent contact with the NSABP site. Figure 1
NSABP Biostatistical Center 
Notifies NSABP Member institutions of eligibility to participate in LTS-01 
NSABP Member Institution 
indicates interest and obtains IRB approval 
for patient recruitment for LTS-01
NSABP Biostatistical Center 
registers the survivor in the LTS-01 study and 
assigns a unique LTS-01 study number 
NSABP Biostatistical Center, UCLA, and NSABP Operations Center
work together to perform data analysis merging CATI data with prior treatment trial-specific data.
UCLA Coordinating Center 
sends telephone interview data to NSABP Biostatistical Center
NSABP Biostatistical Center 
identifies R-02, R-03, C-05, C-06 and C-07 patients who are long-term survivors (5+ years) 
and provides their treatment trial study numbers to the appropriate NSABP Member institution 
NSABP Member Institution 
obtains survivor's consent for contact by UCLA to participate in a 
telephone interview and to allow transfer of personal information 
and submits the consent to NSABP Biostatistical Center 
NSABP Biostatistical Center 
sends information about the survivor registered in LTS-01 to UCLA 
UCLA Coordinating Center
contacts registered survivor, reaffirms consent for the 
interview, and conducts the CATI telephone interview  
Fig. 1 Overview of study pro-
cedures reflecting collaboration
between NSABP, UCLA, and
the NSABP Member Institutions
(clinical sites). CATI=computer-
assisted telephone interview.
J Cancer Surviv (2009) 3:137–147 139provides an overview of the procedures required to identify
and consent long-term CRC survivors for this study.
Institutional recruitment
There were slightly more than 230 NSABP investigators
who were providing long-term data follow-up for the CRC
survivors on the five described protocols. The number of
CRC survivors per investigator ranged from 1 to 110, with
a mean of 12.9 survivors/investigator. This protocol was
approved for cancer control credits by the NCI Division of
Cancer Prevention, and thus all CCOP sites were invited to
participate, as well as the remaining top 30 accruing sites
for the five trials (at least 10 potentially available
survivors). To motivate institutions with a smaller number
of potential participants, as well as to facilitate obtaining
IRB approval, the institutions were supplied the following
supporting materials:
& Model IRB application form, as well as supporting
materials (e.g., copies of questionnaires, study protocol,
UCLA IRB approval for the study)
& Samples of introductory letters to be mailed to potential
participants
& Trifold recruitment brochure that described the study
& Telephone scripts for use by site staff to facilitate
recruitment
& Model informed consent
& Model HIPAA authorization
& Access to technical support from a centralized Coordi-
nating Center via a toll free number and e-mail
correspondence.
& Centralized support to local site coordinators for
assistance in IRB submission, study administration
and patient recruitment
All materials were culturally sensitive to facilitate the
participation of diverse populations. Due to budgetary
limitations, only English speaking survivors could be
included. Once IRB approval for LTS-01 recruitment and
transfer of data was obtained at the local NSABP site, the
investigator and staff were responsible for recruitment of
eligible CRC survivors. The UCLA research team provid-
ed administrative support to the sites in helping them
obtain local IRB approval for the study, as well as
addressing any local challenges related to subject recruit-
ment. Throughout the course of institutional recruitment,
newsletters containing study progress information and
answers to frequently asked questions were sent to
institutions to encourage their participation and survivor
recruitment. In addition, the LTS-01 protocol was featured
both on the scientific program and in nurse-coordinator
workshops at the semi-annual NSABP group meetings.
Finally, targeted recruitment of some non-participating
institutions, including letters to site coordinators, occurred
in the final year of the study, which focused on the barriers
to individual institutional participation. These issues will
b ed i s c u s s e di nd e t a i li no u rr e s u l t s .
Patient recruitment
The anticipated sample size needed for this study across
the 5 trials was 1,167. With recruitment of these 60
institutions, we expected to have available over 2,200
survivors to approach, and we estimated a consent rate of
approximately 50% based on prior studies with recruit-
ment of long-term survivors from tumor registries. To
identify survivors to approach, the NSABP Biostatistical
Center generated the NSABP study numbers of potentially
eligible long-term survivors from the five CRC trials
linked to the respective participating NSABP investigators
and sites. After receiving IRB approval, the NSABP site
investigators were asked to send each identified CRC
survivor an introductory letter and consent form. The letter
described the study and asked for their participation. A
self-addressed stamped envelope was provided for them to
return a response form and the signed consent(s) to the
NSABP Member institution. The response (REC) form
asked the survivor the best times to be contacted for the
telephone survey. If the survivor declined to participate,
the reason for non-participation was collected on the form.
This was also designed to learn about reasons for non-
participation in this type of survey study. Those who did
not respond to the introductory letter within three weeks
were mailed a second letter. If no response was obtained
after two more weeks, and if local IRB policies and
procedures permitted, a follow-up phone call was made by
the local NSABP site staff. If these had not been received
by the subject, a new packet was mailed.
Subjects who agreed to participate in the study mailed
their consent forms along with their preferred contact days
and times to their local site. The local site coordinator
forwarded this information to the NSABP Biostatistical
Center who assigned an identification number to the subject
and forwarded the information to the centralized interview-
ing center at UCLA. Computer assisted telephone inter-
views (CATI) were completed with subjects by a staff of
trained interviewers. The interviewing center corresponded
with the NSABP to address phone numbers that were
disconnected or incorrect. In some cases, the NSABP
corresponded with the local site to obtain the correct
information. Up to ten attempts were made to contact
subjects on their preferred day and time, as well as
additional days and times if necessary. Interviewers’ efforts
to reach subjects included setting appointments and making
calls at a convenient time including early mornings,
evenings, and weekends.
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Institutional recruitment
LTS-01 opened for accrual November 29, 2006, and had an
anticipated recruitment period of 18 months. It was
expected that it would take 3–4 months for institutions to
obtain IRB approval and thereafter they would begin
contacting potential participants. Figure 2 shows the
cumulative rate at which IRB approval was obtained for
those institutions invited to participate. Over time, as we
determined the survivor recruitment was lower than
expected, 5 additional selected institutions with large
numbers of rectal cancer patients received invitations to
participate. Figure 3 shows the results of institutional
recruitment efforts as of January 15, 2009 when the trial
was closed to accrual. Of the 65 institutions that were
invited to participate, initially only 46 indicated interest in
study activation. Of these, 45 successfully obtained IRB
approval and one could not get its IRB to accept
responsibility for the study and recruitment, stating that it
was the responsibility of the protocol investigators con-
ducting the interviews.
Of the 19 institutions that were initially not interested in
participating, a continuous effort was made to work with
these investigators and their data coordinators to overcome
the barriers to obtaining IRB approval. Frequent issues that
came up included: institutions perceiving a lack of available
staffing or time to dedicate to the IRB process and the
subsequent study; institutions perceiving a challenge to
reach subjects due to having many of their eligible subjects
sparsely distributed through multiple satellite sites; satellite
sites lacking resources or interest to initiate their own IRB
processes; institutions encountering challenges/delays in
completing the IRB submission due to technical difficulties
in accessing sample IRB forms or lists of eligible subjects
online; general questions and concerns about the require-
ments of obtaining IRB approval and administering the
study. Ultimately, 12 of these 19 institutions obtained IRB
approval, and the closure date for the study was extended to
accommodate them. Continuous monitoring of institutional
participation and enrollment of the potential target patient
population allowed the research team to identify high yield
institutions that had not joined the study.
Patient recruitment
For the 65 institutions that were invited to participate, we
identified 2,540 potentially eligible survivors to approach
from the 5 CRC adjuvant therapy trials. Figure 3 shows that
among the 2,408 potentially eligible patients from the 60
participating institutions, contact was made with only 976
patients (REC forms received), representing 41 % of the
actual pool. Of these, 744 initially agreed to participate, for
a yield of 76% of those who were contacted. However,
because of our difficulty in contacting these long term
survivors, the overall response rate was 708 of 2,408 or
29%. Table 1 shows the distribution of demographic and
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those finally consenting to participate in this study. Men
and women participated at roughly the same rate. Partic-
ipants in LTS-01 were also younger and more likely to be
white than the total sample who were eligible. As expected,
fewer patients from the older rectal trials (R-02 and R-03)
participated (only 10–16%), and more patients from the
recently completed C-07 trial participated (33%). These
numbers were far below the target accrual of over 1,100
survivors for LTS-01.
Table 2 provides demographic data on 914 patients who
were contacted and provided information about themselves,
indicating whether they would participate and if not, for
what reason. Those who could be contacted and were
willing to participate were significantly younger [(mean age
65.6 vs. 70.2 (P<0.0001)], were more likely to be married
(P=0.05), and were more likely to have been treated more
recently (P=0.018). Reasons for not participating were
recorded on this same form and are described in Table 3.
The most common reason was lack of interest, followed by
staff reporting that patient was either deceased (9 individ-
uals) or unable to be located. In this elderly patient
population, many were in poor health. Among those
categorized as “other” included some patients with recur-
rent cancer, general frailty, being hard of hearing, and
having difficulty locating the patient. Inability to under-
stand and respond in English was rarely cited as a barrier.
Final recruitment through telephone interviews
In total, the UCLA coordinating center received contact
information for 744 subjects and completed 708 (95%)
interviews. Upon reaching a subject, the interviewer read a
script that relayed information about the study and affirmed
Number of
institutions. invited to 
participate in LTS-01
65 
Number of
institutions  
interested 
46 
Number of  IRB 
non-approval 
1 
Number of  IRB
approval 
15 
Number of
institutions not 
interested 
19 
Number of IRB 
non-approval 
4 
Number of  IRB 
approval 
45 
Total number of
pts. submitted 
REC forms 
976 
Number of  pts.  
not interested 
232 
Number of  pts.  
interested 
744 
Total number of
eligible pts.
2408 
Number of  pts.
not submitted
Entry forms 
0 
Number of  pts.
submitted  
Entry forms 
744 
Number of pts.
completed
interview 
708 
Number of pts.
not completed 
interview 
36 
Fig. 3 Flow diagram of institutional and patient recruitment.
142 J Cancer Surviv (2009) 3:137–147the subject’s consent to participate. If the subject affirmed
their consent, the interviewer proceeded with the interview
(n=708). If a subject withdrew their consent, they were
marked as a refusal (n=12). In three cases, subjects were
deemed ineligible at phone contact due to the following
reasons: inability to conduct the interview independently,
inability to conduct the interview in English, and having a
hearing impairment that hindered the ability to hear the
interview over the phone. Subjects who were not reachable
within 10 calls or were not reachable due to irreconcilable
issues with contact information were considered passive
refusals (n=21).
Barriers to institutional recruitment and patient enrollment
Given the large number of potentially eligible patients for
this study, we expected to achieve our target enrollment of
1,167 patients during an 18 month period. Over the course
of the study, we identified several critical barriers that either
delayed or prevented institutional participation. In Table 4
we describe the specific institutional barriers. Over time, we
persisted in pursuing institutions that were reluctant to put
their applications through the IRB and extended additional
financial support to satellite institutions when this was a
barrier. One of the unanticipated barriers was that many of
the patients at each site had been accrued from satellite
institutions, which required additional IRB approvals for
each satellite institution to approach patients. The second
layer of barriers related to the ability to identify and contact
the potentially eligible survivors. There was also consider-
able institutional variability in the yield of patients for
whom contact was obtained, in relationship to the number
of potential participants (See Fig. 4).
Discussion
There is increasing interest in the late effects of specific
treatments for cancer among adult cancer survivors. Some
studies have used large administrative databases, such as
Characteristics Eligible* (%) Participating** (%) (%) Participating/
Eligible
Gender
Male 1,408 (55.43) 427 (57.39) 30.33
Female 1,132 (44.57) 317 (42.61) 28.00
Protocol
C-05 651 (25.63) 157 (21.10) 24.12
C-06 630 (24.80) 186 (25.00) 29.52
C-07 1,038 (40.87) 372 (50.00) 35.84
R-02 153 (6.02) 15 (2.02) 9.80
R-03 68 (2.68) 14 (1.88) 20.59
Disease stage
0 Nodes 1,118 (44.02) 312 (41.94) 27.91
1-3 Nodes 1,044 (41.10) 319 (42.88) 30.56
4+ Nodes 369 (14.53) 111 (14.92) 30.08
Unknown 9 (0.35) 2 (0.27) 22.22
Age***
≤ 59 696 (27.40) 212 (28.49) 30.46
60-69 713 (28.07) 242 (32.53) 33.94
≥70 1131 (44.53) 290 (38.98) 25.64
Mean ± SD 66.60±11.55 65.61±10.53
Race
White or Hispanic 2,283 (89.88) 697 (93.68) 30.53
Black 138 (5.43) 26 (3.49) 18.84
Other 115 (4.53) 20 (2.69) 17.39
Unknown 4 (0.16) 1 (0.13) 25.00
Institution type
Main 1,062 (41.81) 301 (40.46) 28.34
Satellite 1,088 (42.83) 361 (48.52) 33.18
Missing 390 (15.35) 82 (11.02) 21.03
Table 1 Characteristics of
patients eligible for study and
participating in NSABP
LTS-01 study
*Total number of eligible
patients who are in 65 invited
institutions is 2,540
**Total number of participants
is 744
***Age is calculated as of
November 29, 2006 when
the LTS-01 protocol started
to accrue patients
J Cancer Surviv (2009) 3:137–147 143the SEER-Medicare database, that merge tumor registry
identified cases with medical claims data to infer outcomes
from specific therapies, such as the risk for later cardiac
diagnoses after earlier treatment exposure to anthracyclines
[13, 14]. The strength of such studies is the large sample
size and potential for generalizability to the population at
large; however, a major limitation is that these results are
observational, do not account for selection bias in who gets
specific cancer treatments, and inference is made from
coded diagnoses from billing documents rather than from
Table 2 Characteristics of patients with registration screening form available*
Characteristics Total** (%) Agree to participate (%) Not agree to
participate (%)
Fisher’s exact
test P value
Age***
≤ 59 236 (25.82) 212 (28.49) 24 (14.12) <0.0001
60–69 289 (31.62) 242 (32.53) 47 (27.65)
≥70 389 (42.56) 290 (38.98) 99 (58.24)
Mean ± SD 66.48±10.56 65.61±10.53 70.28±9.83
Marital status
Married 651 (72.58) 543 (73.98) 108 (66.26) 0.052
Single, Widowed 246 (27.42) 191 (26.02) 55 (33.74)
Missing 17 10 7
Gender
Male 513 (58.76) 417 (58.82) 96 (58.54) 1.000
Female 360 (41.24) 292 (41.18) 68 (41.46)
Missing 41 35 6
First year of diagnosis
1985–89 13 (1.45) 8 (1.09) 5 (3.07) 0.018
1990–94 197 (22.04) 164 (22.44) 33 (20.25)
1995–99 251 (28.08) 193 (26.40) 58 (35.58)
2000–04 433 (48.43) 366 (50.07) 67 (41.10)
Missing 20 13 7
Ethnicity
Hispanic or Latino 22 (2.74) 18 (2.73) 4 (2.82) 1.000
Not 780 (97.26) 642 (97.27) 138 (97.18)
Unknown 112 84 28
Race#
White Yes 848 (94.01) 692 (94.15) 156 (93.41) 0.718
No 54 (5.99) 43 (5.85) 11 (6.59)
Black Yes 30 (3.33) 25 (3.40) 5 (2.99) 1.000
No 872 (96.67) 710 (96.60) 162 (97.01)
Other Yes 30 (3.33) 24 (3.27) 6 (3.59) 0.812
No 872 (96.67) 711 (96.73) 161 (96.41)
Unknown Yes 12 (1.31) 9 (1.21) 3 (1.76) 0.475
No 902 (98.69) 735 (98.79) 167 (98.24)
*Patients having record of date of birth are included in this table
**Total number of patients is 914
***Age is calculated as of November 29, 2006 when the LTS-01 protocol started to accrue patients
#Some patients might have more than one race
Table 3 Reasons for non-participation on registration screening form
Reasons* Number**(%)
Too busy 22 (9.48)
Experience with cancer too personal/painful 18 (7.76)
Just not interested 72 (31.03)
Other 134 (57.76)
*Some patients have more than one reason
**Total number of non-participants is 232
144 J Cancer Surviv (2009) 3:137–147clinical information in the medical record. These studies
have no data on drug doses or regimen, which may be
critical to understanding late effects. In contrast, studies that
have attempted to link tumor registry samples to abstracted
medical record data often have greater accuracy in
describing late effects, especially when there may be a
dose-response relationship to late effects [15, 16].
Recruitment of long-term survivors directly from
phase III clinical trials databases has great appeal, since
specific treatments are assigned at random as part of the
study design, and thus the interaction of the treatment
exposure with patient characteristics is less likely to be
biased. An important limitation is the highly selective
nature of clinical trial participants in terms of trial eligibility
(e.g., normal kidney, liver function, limited number of
comorbid conditions), as well as the selected nature of the
institutions and patients willing to participate. Nevertheless,
this may be the most effective way to examine the late
effects of specific treatment exposures. Unfortunately, most
clinical trial protocols only monitor toxicity during treat-
ment and do not record late outcomes other than cancer
recurrence and/or death.
Increasingly, various clinical trials groups have made an
effort to obtain long-term data on survivors who were
previously treated on a clinical trial. For example, Champion
et al. [17] recently reported on the quality of life outcomes in
survivors of dysgerminoma recruited from several Gyneco-
logical Oncology Group (GOG) and MD Anderson Cancer
Center trials. There were 238 potentially eligible women
identified from the GOG database, but only 171 (72%) were
from currently active GOG clinical sites. Of these, only 142
were available to contact and 117 participated in the survey
study, representing about 50% of those eligible. A similar
recruitment result occurred for the small number of patients
treated at MD Anderson Cancer Center. The participants
were a median of 10.2 years from diagnosis.
In a study of long-term survivors of breast cancer
survivors treated on CALGB 8541, Paskett et al. [18]
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Table 4 Institutional barriers to study participation
IRB issues
- Issues with content of consent form and/or other study documents
- Central site and satellites — the need for multiple IRBs
Site resources/staffing
- Study not a priority relative to other studies
- Coordinator transitions delay study progress
- Satellites not interested in participating — also impedes central site’s
interest to participate
- Change in principal investigator at a site, no one with an interest in
participating
Trial administration issues
- Satellites had trouble identifying eligible patients on NSABP website
or obtaining eligible patient information from the central site
- Sites are multiple and spread out, so follow-up is perceived to be
difficult
- Time since site’s last contact with patients has been very long, so
follow up is perceived to be difficult
J Cancer Surviv (2009) 3:137–147 145identified 618 survivors who were potentially eligible,
having been treated 9.4–16.5 years earlier. Among these,
245 (40%) completed the survey study. The reasons for
non-accrual included 10% of patients were from non-
CALGB institutions, 10% were lost due to institutions not
opening the survivorship study, in 13% of cases the
institution did not return the eligibility form, 26% of the
sample who were screened were not eligible, 5% were not
invited by the physician, 16% refused, and 7% did not
complete the survey [18]. Thus, there were many chal-
lenges obtaining participation from these survivors so many
years after initial treatment. While the data gathered in this
way are useful, they may be biased towards participation of
the healthiest long-term survivors. For example, as noted in
our study, non-participants tended to be older, not married
and treated during an earlier time period. Such comparison
data were not available in the study by Paskett et al. [18].
In another recent study from the Southwest Oncology
Group (SWOG), Ganz et al. [19] reported on the late
cardiac effects of breast cancer patients treated on SWOG
8897, which compared two different adjuvant chemother-
apy treatments for breast cancer—one containing doxoru-
bicin. This study required participation in a cardiac
evaluation with MUGA scan, as well as medical history
evaluation focused on cardiac events. Patients had to be re-
consented for this follow-up study, which occurred 5–
10 years after the initial clinical trial randomization. In their
study, 1,178 women survivors were available for recruit-
ment to the study and only 180 were registered. Many
SWOG institutions did not open the trial and thus for 69%
of the potential study sample, no attempt was made to
contact them to invite participation in the cardiac follow-up
study. In 13%, administrative and institutional barriers were
responsible for failure to contact potentially eligible sub-
jects. Ineligibility, patient refusal and other reasons
accounted for the other non-participants. While this study
provided valuable comparison data on the two treatment
regimens, the low participation rate limits generalizability
to the entire trial sample [19].
Learning from these experiences with recruitment chal-
lenges in this setting, we designed the LTS-01 study to
provide as much administrative and financial support as
possible to encourage the NSABP institutions to open the
study and recruit the potentially eligible patients. In addition,
we selected the study sites with the largest numbers of
eligible survivors, with the idea that it would not be attractive
for sites with fewer than 10 patients to obtain IRB approval.
We also lessened the burden on the sites by collecting the
patient reported outcome data by telephone at a centralized
location. In spite of these efforts designed to anticipate the
challenges to institutional and patient recruitment, we fell
short of our goal of recruiting about 50% of eligible of
patients.
Some of the new findings from this report are that
patients assigned to a single institution had in fact been
treated at satellites as well as the main institution,
presenting an administrative challenge in terms of number
of IRB approvals required. A related observation was that
some institutions had new clinical and research leadership
that had no personal relationship with patients treated 10–
15 years earlier. Finally, the older age of the patient
population who are colon and rectal cancer survivors was
an important patient-related barrier to recruitment. About
45% of the potentially eligible patients were≥70 years of
age at the time they were approached for participation in
LTS-01. Comorbid illness, frailty, hearing problems and
lack of interest were frequently cited as reasons for non-
participation. Patients treated more recently (e.g., on C-07
clinical trial) were more likely to be participants in LTS-01,
probably reflecting a personal relationship with the clinical
site staff where they were treated, and also being younger.
Also, some patients expressed lack of interest in participat-
ing due to the lower treatment outcome impact of the earlier
trials.
What should be done in the future to facilitate long-
term follow-up studies of patients treated on cancer
clinical trials? With the growing number of cancer
survivors and the limited database on the specific late
effects of cancer treatment, there will be an increasing
need to provide future patients with information about late
effects and long term outcomes of treatment. This is
especially warranted if two treatment strategies have
similar survival outcomes but differing late effects.
Furthermore, if a late effect is common and mutable, high
risk individuals could benefit from late effects screening.
To this end, we suggest that the NCI should consider
providing support and a mechanism for prospective long-
term outcome follow-up in selected clinical trials in adults,
to follow participants prospectively at regular intervals
after treatment, and to maintain some regular contact. This
needs to be built into the initial consent process and
clinical sites will need to be provided with adequate
financial support to maintain contact with participants.
Identification of next of kin or other key contacts, as is
routinely done in long-term epidemiologic studies, will
allow better estimation of biases in loss to follow-up and
non-participation. Furthermore, allowing the cooperative
group to function as a registry for future survivorship
studies would shorten the steps necessary to re-contact
patients and invite them to participate in these late effects
studies. Engaging patients and survivors in the importance
of this aspect of the treatment study will also be important.
Investment in this aspect of the clinical trial research
agenda should be a high priority, as it is very costly, in
terms of personnel and funding to try to locate survivors
many years after a hiatus in contact.
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